Gallenne T, Ross KN, Visser NL, et al. Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer. Oncotarget. 2017;8(13):20572-20587. doi:10.18632/oncotarget.16244
Rheinbay E, Parasuraman P, Grimsby J, et al. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017;547(7661):55-60. doi:10.1038/nature22992
Bi WL, Greenwald NF, Ramkissoon SH, et al. Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology. 2017;158(7):2284-2291. doi:10.1210/en.2016-1967
Goldstein JT, Berger AC, Shih J, et al. Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer. Cancer Res. 2017;77(24):6987-6998. doi:10.1158/0008-5472.CAN-17-1701
Smith ZD, Shi J, Gu H, et al. Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer. Nature. 2017;549(7673):543-547. doi:10.1038/nature23891
Tirosh I, Suvà ML. Dissecting human gliomas by single-cell RNA sequencing. Neuro Oncol. 2018;20(1):37-43. doi:10.1093/neuonc/nox126
Ryan RJH, Petrovic J, Rausch DM, et al. A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell Rep. 2017;21(3):784-797. doi:10.1016/j.celrep.2017.09.066
Sandoval GJ, Hahn WC. Going beyond genetics to discover cancer targets. Genome Biol. 2017;18(1):95. doi:10.1186/s13059-017-1238-7
Hsu JHR, Hubbell-Engler B, Adelmant G, et al. PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer. Cancer Res. 2017;77(17):4613-4625. doi:10.1158/0008-5472.CAN-17-0216
Nakayama RT, Pulice JL, Valencia AM, et al. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. Nat Genet. 2017;49(11):1613-1623. doi:10.1038/ng.3958